Loading...

LIXT LIXTE BIOTECHNOLOGY HOLDINGS INC Business Restructuring 8-K Filing

LXT

LXT

LIXTE BIOTECHNOLOGY HOLDINGS INC

(LIXT)

2025 8-K

Summary

Summary

Digital Currency Purchase

Management Changes

Corporate Update Released

Treasury Policy Update

Regulatory Compliance

Market Expansion

Equity Offerings

Equity Offerings

Convertible Securities

Nasdaq Compliance

New Study Launch

Clinical Update

Clinical Trial Update

Sales Agreement Termination

Clinical Findings

Clinical Trial Update

Nasdaq Compliance

Clinical Trial Update

Earnings Report

Earnings Report

Annual Meeting Results

Clinical Trial Update

Earnings Report

Earnings Report

Earnings Report

Quantitative Data

Other Special Situation

Filing with Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Update on Progress and Fina...

Quantitative Data

Quantitative Data Filing

Financial Update

Annual Meeting Approval

Quantitative Data

Financial Statements and Ea...

Financial Statements and Ea...

Reverse Stock Split

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

External Links:

Lixte Biotechnology Holdings Inc amended its Clinical Trial Agreement with GEIS on March 11, 2025, relieving itself of a financial obligation of approximately $3,095,000 for a Phase 2 study of its drug LB-100, which began in June 2023 and is expected to complete by December 2026.

AI Assistant

LIXTE BIOTECHNOLOGY HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.